Healthcare / BiotechnologyNasdaqCM
$5.98
+0.08 (+1.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-38.9M · quality 62.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$103M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-72.3%
↓Gross Margin
90.3%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-49.5%
FCF / Net income
0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $35.6M · net income $-17.9M · FCF $-17.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $35.6M | $35.6M | $7.6M | $5.1M | $9.0M | $12.0M | — | — | — | — |
| Net Income | $-17.9M | $-17.9M | $-76.6M | $-67.0M | $-24.5M | $-35.1M | $-42.7M | $-28.2M | $-20.6M | $-4.5M |
| EBITDA | $-9.4M | $-9.4M | $-65.9M | $-62.2M | $-21.6M | — | — | — | — | — |
| EPS | -1.68 | -1.68 | -14.80 | -14.80 | -7.20 | -13.00 | — | — | — | — |
| Gross Margin | 90.3% | 90.3% | 63.8% | 85.4% | 92.0% | — | — | — | — | — |
| Operating Margin | -33.6% | -33.6% | -870.2% | -1233.8% | -235.8% | -257.6% | — | — | — | — |
| Net Margin | -50.3% | -50.3% | -1012.1% | -1307.5% | -271.1% | -292.3% | — | — | — | — |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.07 | 0.07 | -4.66 | 2.30 | 0.04 | — | — | — | — | — |
| Current Ratio | 2.10 | 2.10 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-17.6M | $-17.6M | $-61.0M | $-38.9M | $-19.0M | $-28.5M | $-31.7M | $-28.1M | $-18.6M | — |
| Returns | ||||||||||
| ROE | -72.3% | -72.3% | 776.7% | -339.0% | -61.2% | -107.6% | -129.4% | -43.4% | -23.1% | 63.3% |
| Valuation | ||||||||||
| P/B | 2.57 | 2.57 | — | 15.42 | 3.31 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | 370.2% | 370.2% | 47.7% | -43.3% | — | — | — | — | — | — |
| EPS Growth | 88.6% | 88.6% | 0.0% | -105.6% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-14.80 → -1.68
Residual
+10.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.